Zobrazeno 1 - 10
of 80
pro vyhledávání: ''
Autor:
Irene S, Yu, Kathleen, Wee, Laura, Williamson, Emma, Titmuss, Jianghong, An, Sheida, Naderi-Azad, Corey, Metcalf, Stephen, Yip, Basil, Horst, Steven J M, Jones, Katherine, Paton, Brad H, Nelson, Marco, Marra, Janessa J, Laskin, Kerry J, Savage
Publikováno v:
Melanoma Research. 32:278-285
Uveal melanoma is the most common intraocular malignancy and has a poor prognosis compared to other melanoma subtypes with a median overall survival of 6-10 months. With immune checkpoint inhibitor therapy, either PD-1 inhibitor alone or combination
Autor:
Hiroshi Uchi, Satoshi Fukushima, Yuki Yamamoto, Shigeto Matsushita, Hiroshi Kato, Yasuhiro Fujisawa, Ryo Amagai, Takeo Maekawa, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Koji Yoshino, Taku Fujimura
Publikováno v:
Melanoma Research. 31:575-578
Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab
Autor:
Gina Klee, Patrick Terheyden, Jonas K. Kurzhals, Victoria Hagelstein, Detlef Zillikens, Ewan A. Langan, Andreas Recke
Publikováno v:
Melanoma Research. 31:464-471
Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined w
Autor:
Gina Klee, Victoria Hagelstein, J.K. Kurzhals, Detlef Zillikens, Patrick Terheyden, Ewan A. Langan
Publikováno v:
Melanoma research. 32(5)
Despite the dramatic improvement in both overall survival (OS) and progression-free survival (PFS) in patients with metastatic melanoma treated with immune checkpoint inhibitors, up to 60% will develop treatment resistance and 50% will die from their
Autor:
Sarah Guégan, Selim Aractingi, C. Lheure, Gabrielle Goldman-Lévy, Nathalie Franck, Nicolas Dupin, Sandra Huynh, Nora Kramkimel
Publikováno v:
Melanoma Research. 30:317-320
Combined BRAF and MEK inhibition is one of the first-line treatment strategies for patients with advanced BRAF-mutant melanoma. Sarcoid-like reactions (SLRs) have occasionally been described with melanoma systemic treatments such as immunotherapy or
Publikováno v:
Melanoma Res
The use of either immune checkpoint blockade or RAF/MEK inhibitors represents standard of care treatment options for metastatic melanoma. Each class of these drugs has distinct response kinetics, adverse effects, and unique clinical challenges. Combi
Autor:
Benjamin Thomas, Tuan Anh Duong, Gurdeep Parmar, Daniel Brungs, Morteza Aghmesheh, Lucy Haggstrom
Publikováno v:
Melanoma Research. 29:533-538
Disseminated intravascular coagulation is a complex and potentially lethal complication of malignancy, in which the fundamental abnormality is excessive activation of the coagulation system. It is a rare complication of melanoma which can be difficul
Publikováno v:
Melanoma research. 31(4)
Metastatic melanoma is often accompanied by the development of brain metastases, at presentation or during the course of therapy. Local therapies such as surgery and radiation have been considered standard treatments for intracranial disease. However
Autor:
Reinhard Dummer, Valerie C Amann, Anita Giobbie-Hurder, Simone M. Goldinger, Donald P. Lawrence, Lisa Zimmer, Joanna Mangana, Elisabeth Livingstone, Joshua Z. Drago, Tianqi Chen, Alfred Zippelius, Marco Siano, Ryan J. Sullivan
Publikováno v:
Melanoma Research. 29:65-69
BRAF and MEK kinase inhibitors can be highly effective in treating BRAF-mutant melanomas, but their safety and activity in patients with active/symptomatic brain metastases are unclear. We sought to shed light on this open clinical question. We condu
Autor:
Christian U. Blank, Johannes V. Van Thienen, Dieta Brandsma, John B. A. G. Haanen, Willem Boogerd, Marnix H Geukes Foppen
Publikováno v:
Melanoma Research. 28:126-133
Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intr